At a signing event due to be held at Lancaster House today, Sinophi Healthcare CEO Dr Hanif Kanji and Professor Zhao GuoQing, President of the China-Japan Union Hospital of Jilin
Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: “I am delighted to have signed our second commercial purchase order for our LIGHT system. This, and the further Framework Agreements being
Advanced Oncotherapy Plc (LON:AVO) focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN facility in Switzerland.
Beaufort Securities view on Advanced Oncotherapy (LON:AVO): High-power testing of LIGHT’s individual components and modules at this stage is a crucial demonstration of their ability to perform to specifications. Initial
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that the two Coupled Cavity Linac modules are now ready for high-power testing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, confirmed to DirectorsTalk today that its partner for the Chinese market, Sinophi Healthcare Limited, has recently
Advanced Oncotherapy (AIM: AVO) has said this morni9gn to DirectorsTalk that the second Coupled Cavity Linac unit has been manufactured and delivered to the Company’s testing facility in Geneva. The
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that the first tests have begun on the Side Coupled Drift Tube Linac,
Advanced Oncotherapy’s Sanjeev Pandya discusses their $40 million contract win with Sinophi and the 15 year distribution agreement with China in this exclusive interview with DirectorsTalk
It would appear that the technical position of Advanced Oncotherapy (LSE: AVO) has been set fair over the recent past in the sense that the July near vertical breakout for
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
